Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-11-04
2011-11-08
Seaman, D M (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S300000
Reexamination Certificate
active
08053451
ABSTRACT:
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
REFERENCES:
patent: 4192946 (1980-03-01), Clauson-Kaas et al.
patent: 4487607 (1984-12-01), Rose et al.
patent: 4582823 (1986-04-01), Heffner et al.
patent: 4922901 (1990-05-01), Brooks et al.
patent: 5013753 (1991-05-01), Casagrande et al.
patent: 5073547 (1991-12-01), Casagrande et al.
patent: 5187166 (1993-02-01), Kikuchi et al.
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5604231 (1997-02-01), Smith
patent: 5616707 (1997-04-01), Crooks et al.
patent: 5616716 (1997-04-01), Dull et al.
patent: 5663356 (1997-09-01), Ruecroft et al.
patent: 5672601 (1997-09-01), Cignarella
patent: 5726316 (1998-03-01), Crooks
patent: 5811442 (1998-09-01), Ben et al.
patent: 5852041 (1998-12-01), Cosford et al.
patent: 5861423 (1999-01-01), Caldwell
patent: 6232316 (2001-05-01), Dull et al.
patent: 6337351 (2002-01-01), Dull et al.
patent: 6432954 (2002-08-01), Dull et al.
patent: 6492399 (2002-12-01), Dull et al.
patent: 6599897 (2003-07-01), Brown
patent: 6603011 (2003-08-01), Caldwell et al.
patent: 6632823 (2003-10-01), Vernier et al.
patent: 6743812 (2004-06-01), Dull
patent: 6958399 (2005-10-01), Caldwell et al.
patent: 7459469 (2008-12-01), Munoz et al.
patent: 2002/0016460 (2002-02-01), Snow et al.
patent: 2002/0052497 (2002-05-01), Caldwell et al.
patent: 2003/0069272 (2003-04-01), Yerxa et al.
patent: 2004/0044023 (2004-03-01), Cantillon et al.
patent: 2004/0067974 (2004-04-01), Czollner et al.
patent: 2005/0203130 (2005-09-01), Buntinx
patent: 2006/0024358 (2006-02-01), Santini et al.
patent: 2006/0062838 (2006-03-01), Dipierro et al.
patent: 2006/0122237 (2006-06-01), Munoz et al.
patent: 2006/0122238 (2006-06-01), Dull et al.
patent: 2006/0159768 (2006-07-01), Brown
patent: 2007/0265314 (2007-11-01), Dull et al.
patent: 2008/0085888 (2008-04-01), Breining et al.
patent: 2008/0249142 (2008-10-01), Dull et al.
patent: 2009/0062321 (2009-03-01), Munoz et al.
patent: 0297858 (1989-01-01), None
patent: 0516409 (1992-12-01), None
patent: 2295387 (1996-05-01), None
patent: 70012732 (1967-11-01), None
patent: 2002518373 (2002-06-01), None
patent: 2008519768 (2008-06-01), None
patent: 9212122 (1992-07-01), None
patent: 9408992 (1994-04-01), None
patent: 9534555 (1995-12-01), None
patent: 9631475 (1996-10-01), None
patent: 9640682 (1996-12-01), None
patent: 9740011 (1997-10-01), None
patent: 9850367 (1998-11-01), None
patent: 9921834 (1999-05-01), None
patent: 99/65876 (1999-12-01), None
patent: 9965876 (1999-12-01), None
patent: 0007600 (2000-02-01), None
patent: 2004/031151 (2000-08-01), None
patent: 0075110 (2000-12-01), None
patent: 0117943 (2001-03-01), None
patent: 0178735 (2001-10-01), None
patent: 0205801 (2002-01-01), None
patent: 02078693 (2002-10-01), None
patent: 03051302 (2003-06-01), None
patent: 03082205 (2003-10-01), None
patent: 2005/072742 (2004-04-01), None
patent: 2005063296 (2005-07-01), None
patent: 00/45846 (2005-08-01), None
patent: 2005105729 (2005-11-01), None
patent: 2006053039 (2006-05-01), None
patent: 2006053082 (2006-05-01), None
patent: 2006114400 (2006-11-01), None
patent: 2007134034 (2007-11-01), None
patent: 2007134038 (2007-11-01), None
patent: 2007147014 (2007-12-01), None
patent: 2008034041 (2008-03-01), None
patent: 2008073942 (2008-06-01), None
patent: 2008091588 (2008-07-01), None
patent: 2008091592 (2008-07-01), None
Canney et al., Life sciences, (1998) vol. 63, No. 24, pp. PL329-PL336.
Grottick et al., “Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task,” Behav Brain Res. (2000) 117:197-208.
de Costa et al., “Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediam ines as sigma receptor ligands. 1. Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes,” J med Chem (1992) 35(23):4334-4343.
Koller et al., “The Preparation of Substituted Hydroxyphenyl-pyridyl-ethanols and -Hydroxyphenyl—methylpyridineethanols by the Condensation of 2-, 3-, or 4-Picolyllithium with Select Hydroxy-benzaldehydes and 4-Hydroxyacetophenone,” Synthetic Communications (1995) 25(19):2963-2974.
Acheson et al., “Transformations involving the Pyrrolidine Ring of Nicotine,” J Chem Soc (1980) 1:579-585.
Arneric et al., “Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease,” Exp Opin Invest Drugs (1996) 5(1):79-100.
Arneric et al., “Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease,” CNS Drug Rev (1995) 1(1):1-26.
Ashimori et al., “Novel 1, 4-Dihydropyride Calcium Antagonists. I. Synthesis and Hypotensive Activity of 4-(Substittuted Pyridyl)-1,4-dihydropyridine Derivatives” Chem. Pharm Bull (1990) 38(9):2446-2458.
Bannon et al., “Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors,” Science (1998) 279:77-81.
Batkowski, Rocz Chem (1967) 41:729-741.
Bencherif et al., “Targeting Neuronal Nicotinic Receptors: a Path to New Therapies,” Current Drug Targets (2002) 1 (4):349-357.
Bencherif et al., “RJR-2403: A Nicotinic Agonist with CNS Selectivity I: In Vitro characterization,” J Pharmacol Exper Therapeutics (1996) 279(3):1413-1421.
Borch “Reductive Amination with Sodium Cyanoborohydride: N, N-Dimethylcyclohexyl,” Org Syn (1974) 52:124-127.
Brioni et al., “The harmacology of (−)-Nicotine and Novel Cholinergic channel Modulators,” Adv Pharmacol (1997) 37:153-214.
Cai et al., “5-(N-Oxyaza-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically Active and Broad Spectrum An,” J Med Chem (1997) 40(22):3679-3686.
Cheng et al., “Relationship Between the Inhibition Constant (KI) and the Concentration of Inhibitor which Causes 50 Per Cent inhibition (I50) of an Enzymatic Reaction,” (1973) Biochem Pharmacol (1973) 22(23):3099-3108.
Chiari et al., “Sex Differences in Cholinergic Analgesia I: A Supplemental Nicotinic Mechanism in Normal Females,” (1999) Anesthesiology 91(5):1447-1454.
Comins et al., “Lithiation of Methoxypyridines Directed by beta-Amino Alkoxides,” (1990) J Org Chem 91(5):69-73.
Dallacker et al., “,” Naturforsch (1979) 34b:1729-1736.
Damaj et al., “Analgesic Activity of Metanicotine, A Selective Nicotinic Agonist,” Neuroscience (1997) 23:669.
Damaj et al., “Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist,” J Pharmacol Exp Ther (1999) 291(1):390-398.
Decina et al., “Cigarette Smoking and Neuroleptic-Induced Parkinsonism,” Biol Psychiatry (1990) 28(6):502-508.
Dubey et al., “Synthesis & Spectra of 2-Alkyl—& 6-Bromo-2-alkyl-1H-imidazo[b]pyridines,” Indian J Chem (1978) 16B (6):531-533.
Dwoskin et al., “Recent developments in neuronal nicotinic acetylcholine receptor antagonists,” Exp Opin Ther Patents (2000) 10(10):1561-1581.
Frank et al., “Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides,” J Org Chem (1978) 43 (15):2947-2949.
Fr
Genus John
Moore James R.
Munoz Julio A.
Rahmani Niloofar
Seaman D M
Targacept, Inc.
LandOfFree
Hydroxybenzoate salts of metanicotine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxybenzoate salts of metanicotine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxybenzoate salts of metanicotine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293333